Defective adenoviruses and corresponding complementation lines
AssigneeTransgene S.A.
InventorsJean-Luc Imler, Majid Mehtali, Andrea Pavirani
Life of this patent
Estimating the term…
Abstract
Novel defective adenoviruses for the transfer and expression of an exogenous nucleotide sequence in a host cell or organism. The invention also relates to novel complementation lines and to the process for the preparation of these novel defective adenoviruses and their use in therapy and to a pharmaceutical composition containing same.
Claims55
An adenoviral vector which is defective for replication, capable of being encapsidated in a complementation cell, which is derived from the genome of an adenovirus comprising, from 5′ to 3′, a 5′ ITR, an encapsidation region, an E1A region, an E1B region, an E2 region, an E3 region, an E4 region and a 3′ ITR, by deletion of:
- (i) all or part of the E1A region and the whole of the portion of the E1B region coding for the early proteins;
- or
- (ii) all or part of the E1A region and all or part of at least one region selected from E2 and E4 regions;
- or
- (iii) all or part of the E1A region and a portion of the encapsidation region.
A complementation line containing a complementation element, comprising, in particular, a portion of the E1 region of the genome of an adenovirus with the exception of the 5′ ITR;
- said complementation element being capable of complementing in trans a defective adenoviral vector and being integrated in the genome of said complementation line or inserted into an expression vector.
Dependencies are inferred from the claim text.